663 related articles for article (PubMed ID: 16581944)
41. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate.
Naritomi Y; Terashita S; Kagayama A
Xenobiotica; 2004 May; 34(5):415-27. PubMed ID: 15370958
[TBL] [Abstract][Full Text] [Related]
42. Human variation in CYP-specific chlorpyrifos metabolism.
Croom EL; Wallace AD; Hodgson E
Toxicology; 2010 Oct; 276(3):184-91. PubMed ID: 20709133
[TBL] [Abstract][Full Text] [Related]
43. Selective inhibition of CYP2B6-catalyzed bupropion hydroxylation in human liver microsomes in vitro.
Turpeinen M; Nieminen R; Juntunen T; Taavitsainen P; Raunio H; Pelkonen O
Drug Metab Dispos; 2004 Jun; 32(6):626-31. PubMed ID: 15155554
[TBL] [Abstract][Full Text] [Related]
44. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
[TBL] [Abstract][Full Text] [Related]
45. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
[TBL] [Abstract][Full Text] [Related]
46. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin.
Svensson US; Ashton M
Br J Clin Pharmacol; 1999 Oct; 48(4):528-35. PubMed ID: 10583023
[TBL] [Abstract][Full Text] [Related]
47. In vitro characterization of 4'-(p-toluenesulfonylamide)-4-hydroxychalcone using human liver microsomes and recombinant cytochrome P450s.
Lee B; Wu Z; Lee T; Tan XF; Park KH; Liu KH
Xenobiotica; 2016; 46(4):350-6. PubMed ID: 26330107
[TBL] [Abstract][Full Text] [Related]
48. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
[TBL] [Abstract][Full Text] [Related]
49. Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.
Raeissi SD; Guo Z; Dobson GL; Artursson P; Hidalgo IJ
Pharm Res; 1997 Aug; 14(8):1019-25. PubMed ID: 9279883
[TBL] [Abstract][Full Text] [Related]
50. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
Wang JS; DeVane CL
Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
[TBL] [Abstract][Full Text] [Related]
51. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
Jiang R; Yamaori S; Takeda S; Yamamoto I; Watanabe K
Life Sci; 2011 Aug; 89(5-6):165-70. PubMed ID: 21704641
[TBL] [Abstract][Full Text] [Related]
52. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
53. CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems.
Wu Z; Lee D; Joo J; Shin JH; Kang W; Oh S; Lee DY; Lee SJ; Yea SS; Lee HS; Lee T; Liu KH
Antimicrob Agents Chemother; 2013 Nov; 57(11):5448-56. PubMed ID: 23959307
[TBL] [Abstract][Full Text] [Related]
54. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
55. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
56. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.
Ghosal A; Ramanathan R; Yuan Y; Hapangama N; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338
[TBL] [Abstract][Full Text] [Related]
57. Cytochrome P450 specificity of metabolism and interactions of oxybutynin in human liver microsomes.
Lukkari E; Taavitsainen P; Juhakoski A; Pelkonen O
Pharmacol Toxicol; 1998 Apr; 82(4):161-6. PubMed ID: 9584328
[TBL] [Abstract][Full Text] [Related]
58. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
59. Examination of purported probes of human CYP2B6.
Ekins S; VandenBranden M; Ring BJ; Wrighton SA
Pharmacogenetics; 1997 Jun; 7(3):165-79. PubMed ID: 9241656
[TBL] [Abstract][Full Text] [Related]
60. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro.
Chang SY; Li W; Traeger SC; Wang B; Cui D; Zhang H; Wen B; Rodrigues AD
Drug Metab Dispos; 2008 Dec; 36(12):2513-22. PubMed ID: 18787056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
